Leap Therapeutic Stock Price, News & Analysis

Leap Therapeutics (Nasdaq: LPTX), a biotechnology firm focused on immuno-oncology therapeutics, announced that its CEO, Douglas E. Onsi, will present at two virtual investor conferences:

• H.C. Wainwright 23rd Annual Global Investment Conference: September 13, 2021, at 7:00 a.m. ET
• Baird 2021 Global Healthcare Conference: September 15, 2021, at 3:10 p.m. ET

Webcasts of both events will be available on the company's Investor page. Leap is advancing its clinical candidate, DKN-01, targeting multiple cancers.

Leap Therapeutics, Inc. (LPTX) reported a net loss of $9.5 million for Q2 2021, up from $6.5 million in 2020. License revenues remained stable at $0.4 million. Research and development expenses increased to $7.2 million, largely due to higher payroll and clinical trial costs. General and administrative expenses rose to $2.8 million. Cash reserves stood at $35.7 million as of June 30, 2021. The company completed enrollment in the DisTinGuish study for DKN-01 and plans to present initial data at the ESMO Congress in September 2021.

Leap Therapeutics, Inc. (Nasdaq: LPTX) announced its participation in the European Society for Medical Oncology (ESMO) Congress from September 16-21, 2021. The company will present initial findings from the DisTinGuish Phase 2a study, evaluating DKN-01, an anti-DKK1 antibody, combined with tislelizumab in treating gastric or gastroesophageal junction cancer. A conference call is scheduled for September 16, 2021, to discuss these results. The study, involving 25 patients, aims to improve treatment responses in G/GEJ cancer.

Leap Therapeutics (Nasdaq: LPTX) announced that its CEO, Douglas E. Onsi, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 1:00 p.m. ET. The presentation will be available live and as a replay on the company's Investors page.

Leap focuses on targeted and immuno-oncology therapeutics, with its lead candidate, DKN-01, in trials for various cancers. The company has a partnership with BeiGene for DKN-01 development in Asia and oceania.

Leap Therapeutics (Nasdaq: LPTX) announced that Douglas E. Onsi, CEO, will present a corporate overview at the Raymond James 2021 Virtual Human Health Innovation Conference on June 21, 2021, at 1:20 p.m. ET. The presentation will be accessible via the company's Investors page, with a replay available later. Leap is focused on developing immuno-oncology therapeutics, with DKN-01 as its leading candidate targeting DKK1 in various cancer types. The company has partnered with BeiGene for DKN-01 development in several regions excluding Japan.

Leap Therapeutics, Inc. (Nasdaq:LPTX) reported a net loss of $9.1 million for Q1 2021, up from $7.2 million in Q1 2020. The increase was driven by heightened development activities for its DKN-01 program and expanded headcount. License revenues remained steady at $0.4 million. R&D expenses rose to $6.8 million, reflecting more clinical trial costs and staffing. Leap completed enrollment in the DisTinGuish study, evaluating DKN-01 in gastric cancer, and presented promising data on DKN-01's efficacy in gynecological malignancies. Cash reserves stood at $43.5 million as of March 31, 2021.

Leap Therapeutics (Nasdaq: LPTX) and Flagship Biosciences have developed an innovative image analysis RNAscope assay for prospective patient enrollment in clinical trials. This assay, validated in a recent publication, aims to identify patients likely to benefit from the DKN-01 therapy for gastric and gastroesophageal junction adenocarcinoma. The collaboration enhances clinical development through improved screening accuracy and efficiency, utilizing digital analysis to minimize manual errors. The DKN-01 antibody targets the DKK1 protein, linked to poor patient prognosis.

Leap Therapeutics (LPTX) has partnered with Flagship Biosciences to utilize a clinically validated DKK1 RNAscope assay for patient enrollment in their clinical trials. This assay aims to identify patients with high DKK1 levels in gastric cancers for treatment with DKN-01 and tislelizumab. Results presented at the AACR Annual Meeting 2021 confirm the assay's specificity and sensitivity, adhering to CLIA guidelines. The partnership underscores Leap's clinical development strategy, facilitating rapid patient screening and enhancing trial enrollment efficiency.

Leap Therapeutics (Nasdaq:LPTX) announced the completion of enrollment for the first-line patient cohort in the DisTinGuish study, evaluating DKN-01, an anti-Dickkopf-1 antibody, combined with tislelizumab for treating gastric or gastroesophageal junction cancer. The Phase 2a trial will enroll up to 72 patients and aims to address a significant unmet medical need. Initial data is expected in the second half of 2021. DKN-01 has received Orphan Drug and Fast Track Designations from the FDA, highlighting its potential in combating this deadly cancer.